These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 12355959)

  • 41. Clinical efficacy of goserelin (Zoladex) in the treatment of uterine myomas in infertile patients.
    Kopitović V; Bujas M; Fistes Topalski N; Pjević M; Ilić D; Kapamadzija A; Bujas I
    Med Pregl; 2001; 54(7-8):339-46. PubMed ID: 11905182
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
    Daskivich TJ; Oh WK
    Urology; 2006 May; 67(5):1084.e15-7. PubMed ID: 16698377
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Goserelin and locally advanced prostate cancer: new indication. Pros and cons.
    Prescrire Int; 2000 Jun; 9(47):75-6. PubMed ID: 11010743
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
    Cox MC; Scripture CD; Figg WD
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
    Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O; Kontturi M
    Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Long-acting depot of LH-RH agonist].
    Akaza H
    Nihon Rinsho; 2000 Jul; 58 Suppl():309-11. PubMed ID: 11022737
    [No Abstract]   [Full Text] [Related]  

  • 48. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
    Bong GW; Clarke HS; Hancock WC; Keane TE
    Urology; 2008 Jun; 71(6):1177-80. PubMed ID: 18279929
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Study on prevention of flare-up phenomenon following initial LH-RH analogue administration: combination therapy with diethylstilbestrol].
    Takeuchi S; Yoshida K; Tosaka A; Kobayashi N; Higashi Y; Negishi T
    Hinyokika Kiyo; 1995 Mar; 41(3):191-6. PubMed ID: 7741071
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A new longer-acting LHRH analog depot: preliminary results of a Dutch open phase II clinical study on a 10.8 mg Zoladex 3-monthly depot.
    Dijkman GA; Fernandez del Moral P; Plasman JW; Pull HC; van der Meijden AP; Debruyne FM; Hutchinson FG; Furr BJ
    Eur Urol; 1990; 18 Suppl 3():22-5. PubMed ID: 2151271
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Pretreatment with chlormadinone acetate in prostate cancer patients treated with a luteinizing hormone-releasing hormone analogue].
    Yamamoto A; Sumiyoshi Y; Miyake N; Yokozeki H; Kanayama H; Kagawa S
    Hinyokika Kiyo; 1998 Aug; 44(8):557-63. PubMed ID: 9783191
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Skin reaction induced by subcutaneous injection of LH-RH analogue].
    Segawa N; Nishida T; Hamada S; Azuma H; Katsuoka Y; Nozaki K; Tsuji M
    Hinyokika Kiyo; 2007 Oct; 53(10):695-8. PubMed ID: 18018584
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Characteristics, effects, side effects of the LH-RH agonist].
    Miyanaga N; Akaza H
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():177-81. PubMed ID: 12599567
    [No Abstract]   [Full Text] [Related]  

  • 54. LH-RH agonist, Zoladex (Goserelin), depot formulation in the treatment of prostatic cancer. Randomized dose-finding trial in Japan.
    Kotake T; Usami M; Sonoda T; Matsuda M; Okajima E; Osafune M; Isurugi K; Akaza H; Saitoh Y
    Am J Clin Oncol; 1988; 11 Suppl 2():S108-11. PubMed ID: 2977262
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [A comparative efficacy study of the preoperative use of GnRH agonists in women with uterine fibromyomas].
    Nikolov A; Karag'ozov I
    Akush Ginekol (Sofiia); 1999; 38(4):38-42. PubMed ID: 10726353
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Phase I study with LH-RH agonist, ICI 118630].
    Usami M; Kotake T; Sonoda T
    Hinyokika Kiyo; 1986 Mar; 32(3):493-501. PubMed ID: 2942018
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Dynamic study of the hormonal levels and tumor markers after the first administration of long-acting LH-RH analogue in patients with prostate cancer].
    Takeuchi S; Yoshida K; Tosaka A; Kobayashi N; Uchijima Y; Saitoh H
    Hinyokika Kiyo; 1994 May; 40(5):393-400. PubMed ID: 7517620
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
    Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
    J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog].
    Fuse H; Akimoto S; Akakura K; Shimazaki J; Murakami S
    Hinyokika Kiyo; 1988 Mar; 34(3):555-60. PubMed ID: 3133936
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex).
    Walker KJ; Turkes AO; Turkes A; Zwink R; Beacock C; Buck AC; Peeling WB; Griffiths K
    J Endocrinol; 1984 Nov; 103(2):R1-4. PubMed ID: 6238116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.